NCT04497597

A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Upadacitinib Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Moderate to Severe Rheumatoid Arthritis Patients in Real-World Practice (UPHOLD)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,532 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the treatment patterns, achievement of treatment targets and maintenance of response. Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. Adult participants with moderate to severe RA who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 1660 participants will be enrolled this study, worldwide. Participants will not receive Upadacitinib as part of this study, but will be followed for response to treatment for up to 24 months. There may be higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits, every 3 months, during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.

Conditions

• Rheumatoid Arthritis (RA)

Timeline

• Start date: 2020-10-16
• Primary completion: 2024-05-15
• Completion: 2024-05-15
• First posted: 2020-08-04
• Last updated: 2025-04-13

Locations

263 sites across 19 countries: Argentina, Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Kuwait, Mexico, Russia, Saudi Arabia, Spain, Switzerland, Taiwan, United Arab Emirates, Uruguay